127 related articles for article (PubMed ID: 9988595)
1. Studies to establish quality control ranges for SB-265805 (LB2030) when using National Committee for Laboratory Standards antimicrobial susceptibility test methods. Quality Control Study Group.
Erwin ME; Jones RN
J Clin Microbiol; 1999 Jan; 37(1):279-80. PubMed ID: 9988595
[No Abstract] [Full Text] [Related]
2. In vitro activity of gemifloxacin and five other fluoroquinolones against defined isogenic mutants of Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus.
Schulte A; Heisig P
J Antimicrob Chemother; 2000 Dec; 46(6):1037-8. PubMed ID: 11102429
[No Abstract] [Full Text] [Related]
3. Evaluation of in vitro susceptibility testing criteria for gemifloxacin when tested against Haemophilus influenzae strains with reduced susceptibility to ciprofloxacin and ofloxacin.
Biedenbach DJ; Jones RN
Diagn Microbiol Infect Dis; 2002 Aug; 43(4):323-6. PubMed ID: 12151195
[TBL] [Abstract][Full Text] [Related]
4. Comparative in vitro activity of the new quinolone gemifloxacin (SB-265805) with other fluoroquinolones against respiratory tract pathogens.
García-Garrote F; Cercenado E; Martín-Pedroviejo J; Cuevas O; Bouza E
J Antimicrob Chemother; 2001 May; 47(5):681-4. PubMed ID: 11328784
[TBL] [Abstract][Full Text] [Related]
5. The bactericidal activity of gemifloxacin (SB-265805).
Morrissey I; Clark S; Mathias I
J Med Microbiol; 2000 Sep; 49(9):841-844. PubMed ID: 10966234
[TBL] [Abstract][Full Text] [Related]
6. Staphylococcus aureus and Escherichia coli adhesion to human cells is reduced by sub-MICs of gemifloxacin.
Braga PC; Dal SM; Woodnutt G
J Chemother; 2002 Feb; 14(1):41-6. PubMed ID: 11892898
[TBL] [Abstract][Full Text] [Related]
7. Comparative in vitro activities of five quinolone antibiotics, including gemifloxacin, against clinical isolates.
Gönüllü N; Aktaş Z; Salcioglu M; Bal C; Ang O
Clin Microbiol Infect; 2001 Sep; 7(9):499-503. PubMed ID: 11678934
[TBL] [Abstract][Full Text] [Related]
8. Gemifloxacin and ciprofloxacin pharmacodynamics in an in-vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and doses.
Firsov AA; Zinner SH; Lubenko IYu ; Vostrov SN
Int J Antimicrob Agents; 2000 Dec; 16(4):407-14. PubMed ID: 11118849
[TBL] [Abstract][Full Text] [Related]
9. Comparative in vitro potency of gemifloxacin against European respiratory tract pathogens isolated in the Alexander Project.
Marchese A; Debbia EA; Schito GC
J Antimicrob Chemother; 2000 Jul; 46 Suppl T1():11-5. PubMed ID: 10997594
[TBL] [Abstract][Full Text] [Related]
10. Comparative in vitro activity of gemifloxacin to other fluoroquinolones and non-quinolone agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States in 1999-2000.
Koeth LM; Jacobs MR; Bajaksouzian S; Zilles A; Lin G; Appelbaum PC
Int J Antimicrob Agents; 2002 Jan; 19(1):33-7. PubMed ID: 11814765
[TBL] [Abstract][Full Text] [Related]
11. Development of in vitro susceptibility testing methods for gemifloxacin (formerly LB20304a or SB-265805), an investigational fluoronaphthyridone.
Jones RN; Erwin ME; Biedenbach DJ; Johnson DM; Pfaller MA
Diagn Microbiol Infect Dis; 1999 Nov; 35(3):227-34. PubMed ID: 10626134
[TBL] [Abstract][Full Text] [Related]
12. The in-vitro activity and tentative breakpoint of gemifloxacin, a new fluoroquinolone.
Wise R; Andrews JM
J Antimicrob Chemother; 1999 Nov; 44(5):679-88. PubMed ID: 10552986
[TBL] [Abstract][Full Text] [Related]
13. Species-independent pharmacodynamics of gemifloxacin and ciprofloxacin with Haemophilus influenzae and Moraxella catarrhalis in an in vitro dynamic model.
Portnoy YA; Vostrov SN; Lubenko IY; Zinner SH; Firsov AA
Int J Antimicrob Agents; 2002 Sep; 20(3):201-5. PubMed ID: 12385699
[TBL] [Abstract][Full Text] [Related]
14. Comparative anti-staphylococcal effects of gemifloxacin and trovafloxacin in an in vitro dynamic model in terms of AUC/MIC and dose relationships.
Zinner SH; Vostrov SN; Lubenko IY; Portnoy YA; Cornaglia G; Firsov AA
Diagn Microbiol Infect Dis; 2001 Aug; 40(4):167-71. PubMed ID: 11576789
[TBL] [Abstract][Full Text] [Related]
15. Urine bactericidal activity after administration of gemifloxacin and trovafloxacin single doses in a phase I study.
García-Calvo G; Parra A; Ponte C; Soriano F; Giménez MJ; Aguilar L
Int J Antimicrob Agents; 2002 Dec; 20(6):477-80. PubMed ID: 12458147
[No Abstract] [Full Text] [Related]
16. Comparison of agar dilution, microdilution, Etest and disc diffusion to test the activity of trovafloxacin against Pseudomonas aeruginosa, methicillin-resistant Staphylococcus aureus and Streptococcus pneumoniae.
Kelly LM; Jacobs MR; Appelbaum PC
J Antimicrob Chemother; 1999 May; 43(5):707-9. PubMed ID: 10382894
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility of European respiratory tract isolates to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillin.
Pontani D; Washton H; Bouchillon S; Johnson J
Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):413-9. PubMed ID: 9758284
[TBL] [Abstract][Full Text] [Related]
18. Assessment of BMS284756 MIC and 5-microg disk diffusion quality control studies tested against seven American type culture collection strains.
Biedenbach DJ; Jones RN;
Diagn Microbiol Infect Dis; 2001 Dec; 41(4):225-8. PubMed ID: 11777665
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA.
McCloskey L; Moore T; Niconovich N; Donald B; Broskey J; Jakielaszek C; Rittenhouse S; Coleman K
J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():13-21. PubMed ID: 10824027
[TBL] [Abstract][Full Text] [Related]
20. Interpretive criteria and quality control parameters for testing bacterial susceptibility to the fluoroquinolone PD131628.
Barry AL; Fuchs PC; Allen SD; Tenover FC; Jorgensen JH; Reller LB
J Clin Microbiol; 1995 Jan; 33(1):235-8. PubMed ID: 7699050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
